VolitionRX Financials - Benzinga

VolitionRX Ltd

VNRXAMEX

Trade with Public

Trade with Public

$0.4493

-0.0517-10.32%

al cierre: Aug 28, 5:00 PM EST

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivoFinanzasSentimiento Propiedad Comparar Informe de acciones

VolitionRX Financials

VolitionRX (VNRX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
VolitionRX Q2 EPS $(0.85) Misses $(0.57) Estimate, Sales $398.657K Miss $482.667K Estimate

VolitionRX (AMEX:VNRX) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.57) by 49.12 percent. This is a 1316.67 percent decrease over losses of $(0.06) per share from the

Benzinga Newsdesk

PRO
VolitionRX Q1 EPS $(0.97) Misses $(0.75) Estimate, Sales $985.076K Beat $426.600K Estimate

VolitionRX (AMEX:VNRX) reported quarterly losses of $(0.97) per share which missed the analyst consensus estimate of $(0.75) by 29.33 percent. This is a 1516.67 percent decrease over losses of $(0.06) per share from the

Benzinga Newsdesk

Earnings Scheduled For May 14, 2026

Benzinga Insights

PRO
VolitionRX Q4 EPS $(0.05), Inline, Sales $447.034K Miss $765.167K Estimate

VolitionRX (AMEX:VNRX) reported quarterly losses of $(0.05) per share which met the analyst consensus estimate. This is a 16.67 percent increase over losses of $(0.06) per share from the same period last year. The

Benzinga Newsdesk

Earnings Scheduled For March 31, 2026

Benzinga Insights

PRO
VolitionRX Q3 EPS $(0.05) Misses $(0.04) Estimate, Sales $627.277K Miss $1.681M Estimate

VolitionRX (AMEX:VNRX) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 13.64 percent. This is a 28.57 percent increase over losses of $(0.07) per share from the

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved